Total Payments
$4,388
2024 Payments
$651.23
Companies
33
Transactions
242
Medicare Patients
4,183
Medicare Billing
$589,144
Payment Breakdown by Category
Food & Beverage$4,330 (98.7%)
Education$57.48 (1.3%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,330 | 241 | 98.7% |
| Education | $57.48 | 1 | 1.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $1,176 | 78 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $782.24 | 48 | $0 (2024) |
| GENZYME CORPORATION | $304.11 | 14 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $235.73 | 11 | $0 (2023) |
| PFIZER INC. | $147.56 | 9 | $0 (2022) |
| Regeneron Healthcare Solutions, Inc. | $129.11 | 6 | $0 (2024) |
| Actelion Pharmaceuticals US, Inc. | $126.50 | 6 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $123.50 | 1 | $0 (2019) |
| Genentech USA, Inc. | $123.39 | 6 | $0 (2023) |
| Amgen Inc. | $119.33 | 5 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $651.23 | 33 | GlaxoSmithKline, LLC. ($264.87) |
| 2023 | $981.76 | 51 | GlaxoSmithKline, LLC. ($167.32) |
| 2022 | $992.62 | 52 | AstraZeneca Pharmaceuticals LP ($250.55) |
| 2021 | $958.87 | 62 | GlaxoSmithKline, LLC. ($299.11) |
| 2020 | $373.30 | 23 | GlaxoSmithKline, LLC. ($158.31) |
| 2019 | $179.76 | 5 | E.R. Squibb & Sons, L.L.C. ($123.50) |
| 2018 | $129.89 | 9 | AstraZeneca Pharmaceuticals LP ($45.69) |
| 2017 | $120.37 | 7 | PFIZER INC. ($65.03) |
All Payment Transactions
242 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2024 | Azurity Pharmaceuticals, Inc. | HORIZANT (Drug) | Food and Beverage | In-kind items and services | $21.29 | General |
| Category: CEREBROVASCULARCNS | ||||||
| 12/12/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $10.78 | General |
| Category: RESPIRATORY | ||||||
| 12/06/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $15.95 | General |
| Category: Respiratory | ||||||
| 12/04/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $8.28 | General |
| Category: RESPIRATORY | ||||||
| 11/13/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $11.29 | General |
| Category: IMMUNOLOGY | ||||||
| 11/07/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $14.64 | General |
| Category: Respiratory | ||||||
| 10/25/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ARALAST (Biological) | Food and Beverage | In-kind items and services | $16.98 | General |
| Category: IMMUNOLOGY | ||||||
| 10/23/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $14.16 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 10/22/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $8.80 | General |
| Category: RESPIRATORY | ||||||
| 10/21/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $17.99 | General |
| Category: IMMUNOLOGY | ||||||
| 10/08/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $18.38 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/07/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $10.65 | General |
| Category: RESPIRATORY | ||||||
| 09/26/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $22.32 | General |
| Category: Immunology | ||||||
| 09/24/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Food and Beverage | In-kind items and services | $18.34 | General |
| Category: NEUROLOGY | ||||||
| 09/24/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $17.95 | General |
| Category: IMMUNOLOGY | ||||||
| 09/24/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $7.59 | General |
| Category: IMMUNOLOGY | ||||||
| 09/18/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $18.78 | General |
| Category: IMMUNOLOGY | ||||||
| 07/25/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $12.58 | General |
| Category: RESPIRATORY | ||||||
| 07/24/2024 | Philips North America LLC | (AK6) Vest Therapy (Device) | Food and Beverage | Cash or cash equivalent | $15.77 | General |
| Category: Medical Device | ||||||
| 07/23/2024 | Amgen Inc. | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $16.71 | General |
| Category: Inflammation | ||||||
| 07/22/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $6.49 | General |
| Category: IMMUNOLOGY | ||||||
| 07/09/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: RESPIRATORY | ||||||
| 07/09/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $16.50 | General |
| Category: Respiratory | ||||||
| 03/06/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $8.69 | General |
| Category: RESPIRATORY | ||||||
| 02/28/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $24.45 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 855 | 1,209 | $314,058 | $124,956 |
| 2022 | 18 | 1,076 | 1,672 | $379,104 | $155,906 |
| 2021 | 21 | 1,440 | 2,249 | $528,075 | $226,662 |
| 2020 | 18 | 812 | 1,052 | $183,023 | $81,619 |
Total Patients
4,183
Total Services
6,182
Medicare Billing
$589,144
Procedure Codes
71
All Medicare Procedures & Services
71 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 132 | 312 | $143,520 | $51,241 | 35.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 254 | 344 | $66,392 | $31,308 | 47.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 104 | 172 | $32,164 | $15,806 | 49.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 62 | 62 | $22,444 | $8,218 | 36.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 46 | 46 | $13,432 | $5,775 | 43.0% |
| 71271 | Low dose ct scan of chest for lung cancer screening | Office | 2023 | 16 | 16 | $6,800 | $2,246 | 33.0% |
| 99292 | Critical care, each additional 30 minutes | Facility | 2023 | 24 | 26 | $5,850 | $2,092 | 35.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 18 | 18 | $4,446 | $1,818 | 40.9% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2023 | 73 | 82 | $5,330 | $1,648 | 30.9% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 28 | 28 | $2,940 | $1,243 | 42.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 20 | 20 | $2,700 | $1,229 | 45.5% |
| 94726 | Test to determine lung volumes using sensors | Office | 2023 | 27 | 27 | $3,105 | $1,094 | 35.2% |
| 94618 | Test for exercise-induced lung stress | Office | 2023 | 32 | 36 | $3,435 | $832.22 | 24.2% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 19 | 20 | $1,500 | $407.84 | 27.2% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 169 | 377 | $173,420 | $64,226 | 37.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 189 | 343 | $55,375 | $31,363 | 56.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 127 | 243 | $43,740 | $19,162 | 43.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 63 | 64 | $21,120 | $9,748 | 46.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 87 | 137 | $18,495 | $7,557 | 40.9% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 47 | 49 | $11,270 | $5,195 | 46.1% |
| 99292 | Critical care, each additional 30 minutes | Facility | 2022 | 43 | 50 | $11,250 | $4,248 | 37.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 35 | 35 | $8,669 | $3,947 | 45.5% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2022 | 103 | 150 | $9,750 | $2,897 | 29.7% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2022 | 49 | 52 | $5,460 | $2,063 | 37.8% |
| 94726 | Test to determine lung volumes using sensors | Office | 2022 | 46 | 49 | $5,635 | $1,833 | 32.5% |
About Dr. Abhishek Agarwal, MD
Dr. Abhishek Agarwal, MD is a Pulmonary Disease healthcare provider based in Marlton, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/23/2014. The National Provider Identifier (NPI) number assigned to this provider is 1417365438.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Abhishek Agarwal, MD has received a total of $4,388 in payments from pharmaceutical and medical device companies, with $651.23 received in 2024. These payments were reported across 242 transactions from 33 companies. The most common payment nature is "Food and Beverage" ($4,330).
As a Medicare-enrolled provider, Agarwal has provided services to 4,183 Medicare beneficiaries, totaling 6,182 services with total Medicare billing of $589,144. Data is available for 4 years (2020–2023), covering 71 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Other Specialties Student in an Organized Health Care Education/Training Program, Pulmonary Disease
- Location Marlton, NJ
- Active Since 07/23/2014
- Last Updated 11/21/2024
- Taxonomy Code 207RP1001X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1417365438
Products in Payments
- NUCALA (Biological) $504.37
- DUPIXENT (Biological) $490.70
- TRELEGY ELLIPTA (Drug) $466.37
- TEZSPIRE (Biological) $276.10
- ELIQUIS (Drug) $215.04
- FASENRA (Biological) $180.69
- AREXVY (Drug) $145.55
- OFEV (Drug) $144.50
- BREZTRI (Drug) $140.27
- Xolair (Biological) $123.39
- XARELTO (Drug) $98.47
- STIOLTO RESPIMAT (Drug) $91.23
- SMARTVEST (Device) $82.52
- UPTRAVI (Drug) $81.74
- PURIFIED CORTROPHIN GEL (Drug) $77.07
- XYWAV (Drug) $76.00
- YUPELRI (Drug) $69.20
- Arikayce (Drug) $67.96
- FASENRA (Drug) $51.59
- GLASSIA (Biological) $48.21
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Marlton
Dr. Mark Weir, Mb Chb, MB CHB
Pulmonary Disease — Payments: $7,553
Pulmonary Disease $7,553
Dr. Eric Sztejman, Md, MD
Pulmonary Disease — Payments: $4,910
Pulmonary Disease $4,910
Dr. Emilio Mazza, Md, MD
Pulmonary Disease — Payments: $4,892
Pulmonary Disease $4,892
Allen Salm, Md, MD
Pulmonary Disease — Payments: $4,688
Pulmonary Disease $4,688
Matthew Gordon, Md, MD
Pulmonary Disease — Payments: $4,385
Pulmonary Disease $4,385
Dr. Jonathan Galli, M.d, M.D
Pulmonary Disease — Payments: $3,450
Pulmonary Disease $3,450